A carregar...
Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis?
BACKGROUND: Decreased relapse rate and slower disease progression have been reported with long-term use of immunomodulatory treatments (IMTs, interferon beta or glatiramer acetate) in relapsing–remitting multiple sclerosis. There are, however, patients who do not respond to such treatments, and they...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3484901/ https://ncbi.nlm.nih.gov/pubmed/23118540 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S36771 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|